| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,410,000 |
| Market
Cap: |
691.56(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.21 - $21.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
128,310 |
194,896 |
224,296 |
274,612 |
| Total Sell Value |
$2,726,499 |
$3,969,036 |
$4,531,208 |
$5,316,305 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
8 |
12 |
14 |
16 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2023-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,992 |
52,566 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2023-09-01 |
4 |
D |
$17.76 |
$14,048 |
D/D |
(791) |
14,318 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2023-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,695 |
15,109 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2023-07-25 |
4 |
AS |
$18.01 |
$555,160 |
D/D |
(29,000) |
41,910 |
|
-17% |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2023-07-25 |
4 |
OE |
$1.86 |
$53,940 |
D/D |
29,000 |
70,910 |
|
- |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2023-07-15 |
4 |
A |
$12.35 |
$3,606 |
D/D |
292 |
12,845 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2023-07-15 |
4 |
A |
$12.35 |
$7,175 |
D/D |
581 |
13,558 |
|
- |
|
| Levy Richard S |
|
– • – |
2023-06-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Malley Thomas |
|
– • – |
2023-06-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Mccain Tracey L |
|
– • – |
2023-06-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Popovits Kimberly J |
|
– • – |
2023-06-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Cole G Bradley |
|
– • – |
2023-06-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Quart Barry D |
|
– • – |
2023-06-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • – |
2023-06-06 |
4 |
A |
$0.00 |
$0 |
I/I |
17,492 |
2,719,343 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2023-04-26 |
4 |
D |
$11.15 |
$3,245 |
D/D |
(291) |
12,414 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2023-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
990 |
12,705 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2023-04-10 |
4 |
D |
$10.71 |
$8,579 |
D/D |
(801) |
120,067 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2023-04-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,727 |
120,868 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2023-04-10 |
4 |
D |
$10.71 |
$8,472 |
D/D |
(791) |
11,715 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2023-04-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,695 |
12,506 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2023-04-10 |
4 |
D |
$10.71 |
$12,370 |
D/D |
(1,155) |
12,977 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2023-04-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,933 |
14,132 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2023-04-10 |
4 |
D |
$10.71 |
$7,861 |
D/D |
(734) |
41,910 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2023-04-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,498 |
42,644 |
|
- |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2023-04-10 |
4 |
D |
$10.71 |
$14,491 |
D/D |
(1,353) |
12,553 |
|
- |
|
241 Records found
|
|
Page 4 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.66 (3.27%) 
